MASCC Webinar: ADC Toxicities in the Real World: Recognize, Differentiate, Act

Learning Objectives:

As antibody-drug conjugates (ADCs) move into more treatment settings and are increasingly used alongside other systemic therapies, clinicians face a more complicated supportive care challenge: anticipating toxicity, determining what is causing it, and knowing when and how to intervene.

Leading experts will explore practical approaches to neutropenia, nausea and vomiting, diarrhea, mucositis and ocular toxicity across TROP2 ADC therapies.

By the end of this session, participants will be able to:

• Describe how toxicity profiles differ across TROP2 ADC therapies and how these differences may affect supportive care strategies
• Discuss risk assessment for neutropenia and how to optimize growth factor prophylaxis associated with ADC therapy, including practical considerations for primary versus secondary prophylaxis and the timing of short-acting G-CSF
• Review strategies for the prevention and management of nausea and vomiting associated with ADC therapy, as well as strategies for managing gastrointestinal (acute and chronic diarrhea) and oral toxicities
• Recognize ADC-associated ocular toxicities, differentiate concerning symptoms, and implement appropriate monitoring, referral, and treatment-management strategies
• Apply a proactive, patient-centered approach to ADC toxicity management that supports quality of life and continuation of effective cancer therapy
• Identify supportive care strategies across ADCs to reduce toxicity burden and support treatment continuity